Twinning for Excellence in Research, Training and Innovation in Protein Misfolding Diseases

蛋白质错误折叠疾病研究、培训和创新领域的卓越结对

• 批准号: 10059436
• 金额: $ 32.64万
• 依托单位: UNIVERSITY OF CAMBRIDGE
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10059436
• 关键词: Twinning; Excellence; Research; Training; Innovation

Protein misfolding diseases (PMDs) are a large group of human disorders caused by protein misfolding and include serious conditions with high socio-economic impact, such as Alzheimer’s disease, systemic amyloidosis, obesity, cystic fibrosis, retinitis pigmentosa and type 2 diabetes. The vast majority of them remain incurable so there is currently a great need for the development of effective therapeutics against them. Among the >70 known PMDs, about one third occur due to the misfolding of integral membrane proteins (MPs). MPs, however, are notoriously difficult to overexpress, isolate and study, both biochemically and structurally, thus constituting particularly challenging targets for therapeutic intervention with only few lead molecules in (pre)clinical pipelines. Furthermore, the scientific community involved in PMDs remains fragmented, with the majority of research targeting soluble proteins and only a small, rather isolated, sub-community focusing on misfolding-prone MPs. The National Hellenic Research Foundation has been exploiting the power of synthetic biology to develop efficient technologies targeting the misfolding of both soluble and membrane proteins. The coordinator wishes to build on these initial successes to partner with three prominent centers in PMD and synthetic biology research in order to establish a new excellence hub in research, training and innovation in PMDs and consolidate the scientific community in this field. Through this process, it will acquire a position among the leaders in the field of PMDs and converge with the most advanced institutions in terms of the quality of scientific data it produces, number of top-tier of scientific papers it publishes, amount of funding it secures from competitive sources, efficiency with which it trains its young scientists and contributes to their career development, the way it communicates the results of its research activity and converts them to tangible outcomes for high-tech entrepreneurship and the societyno public description

蛋白质错误折叠疾病（PMD）是由蛋白质错误折叠引起的一大组人类疾病，并且包括具有高社会经济影响的严重病症，例如阿尔茨海默病、系统性淀粉样变性、肥胖、囊性纤维化、色素性视网膜炎和2型糖尿病。他们中的绝大多数仍然无法治愈，因此目前非常需要开发针对他们的有效治疗方法。在超过70种已知的PMD中，约三分之一是由于整合膜蛋白（MP）的错误折叠而发生的。然而，众所周知，MP在生物化学和结构上都难以过表达、分离和研究，因此在（预）临床管道中仅用很少的先导分子就构成了用于治疗干预的特别具有挑战性的靶标。此外，参与PMD的科学界仍然是分散的，大多数研究针对可溶性蛋白质，只有一个小的，相当孤立的，子社区集中在错误折叠的MP。希腊国家研究基金会一直在利用合成生物学的力量开发针对可溶性和膜蛋白错误折叠的有效技术。协调员希望在这些初步成功的基础上，与PMD和合成生物学研究的三个著名中心合作，以建立PMD研究，培训和创新的新卓越中心，并巩固该领域的科学界。通过这一过程，它将在PMD领域的领导者中占据一席之地，并在其产生的科学数据质量，发表的顶级科学论文数量，从竞争来源获得的资金数量，培训年轻科学家并为其职业发展做出贡献的效率方面与最先进的机构趋同，它传播其研究活动成果并将其转化为高科技创业和社会的有形成果的方式